BY APPOINTMENT ONLY!
If you’re over 45? Or Clinically extremely vulnerable
Parkview Pharmacy will be running their Covid-19 Vaccination Programme from Thursday 21st January 2021. The Vaccination will take place inside a purpose built hub at the rear of the main pharmacy. Please follow arrows provided, note vaccines are currently given strictly by appointment only.
The hub will be supervised at all times by a GPHC Registered Pharmacist
If you have a query regarding our Covid-19 Vaccination Programme, please do not call the practice. Instead please contact via our form staff member will try and contact you within 72 hours. Please note that we cannot book appointments or respond to emergencies on this email.
If attending the practice for Covid-19 Vaccination Clinics (or any other reason) please ensure that you wear a face covering or mask at all times.
Note: The main covid centre is not accessible via wheelchair,
please ask in Pharmacy for assistance.
There is ample parking on the parade in front of the shops on Bramley road and also on South Lodge Drive and Belgrave Gardens (The 2-3pm parking restrictions have been waived until 30th April 2021 at least)
Join our waiting list
Definition of clinically extremely vulnerable groups
People who are defined as clinically extremely vulnerable are at very high risk of severe illness from coronavirus. There are 2 ways you may be identified as clinically extremely vulnerable:
- You have one or more of conditions listed below, or
- Your clinician or GP has added you to the Shielded Patient List because, based on their clinical judgement, they deem to you be at higher risk of serious illness if you catch the virus.
If you do not fall into any of these categories, and have not been contacted to inform you that you are on the Shielded Patient List, follow the national lockdown guidance for the rest of the population.
If you think there are good clinical reasons why you should be added to the Shielded Patient List, discuss your concerns with your GP or hospital clinician. People with the following conditions are automatically deemed clinically extremely vulnerable:
|
Appendix 1 |
|
|
Green Book at risk category |
Green Book full definition |
|
Chronic respiratory disease |
Individuals with a severe lung condition, including those with asthma that requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission, and chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema; bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and bronchopulmonary dysplasia (BPD). |
|
Chronic heart disease and vascular disease |
Congenital heart disease, hypertension with cardiac complications, chronic heart failure, individuals requiring regular medication and/or follow-up for ischaemic heart disease. This includes individuals with atrial fibrillation, peripheral vascular disease or a history of venous thromboembolism. |
| Chronic kidney disease | Chronic kidney disease at stage 3, 4 or 5, chronic kidney failure, nephrotic syndrome, kidney transplantation. |
| Chronic liver disease | Cirrhosis, biliary atresia, chronic hepatitis. |
|
Chronic neurological disease |
Stroke, transient ischaemic attack (TIA). Conditions in which respiratory function may be compromised due to neurological disease (e.g. polio syndrome sufferers). This includes individuals with cerebral palsy, severe or profound learning disabilities, Down’s Syndrome, multiple sclerosis, epilepsy, dementia, Parkinson’s disease, motor neurone disease and related or similar conditions; or hereditary and degenerative disease of the nervous system or muscles; or severe neurological disability. |
| Diabetes mellitus | Any diabetes, including diet-controlled diabetes. |
|
Immunosuppression |
Immunosuppression due to disease or treatment, including patients undergoing chemotherapy leading to immunosuppression, patients undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID). Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil. Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults. Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma and those with systemic lupus erythematosus and rheumatoid arthritis, and psoriasis who may require long term immunosuppressive treatments. Most of the more severely immunosuppressed individuals in this group should already be flagged as CEV. Individuals who are not yet on the CEV list but who are about to receive highly immunosuppressive interventions or those whose level of immunosuppression is about to increase may be therefore be offered vaccine alongside the CEV group, if therapy can be safely delayed or there is sufficient time (ideally two weeks) before therapy commences. Some immunosuppressed patients may have a suboptimal immunological response to the vaccine (see Immunosuppression and HIV). |
| Asplenia or dysfunction of the spleen | This also includes conditions that may lead to splenic dysfunction, such as homozygous sickle cell disease, thalassemia major and coeliac syndrome. |
| Morbid obesity | Adults with a Body Mass Index ≥40 kg/m² |
| Severe mental illness | Individuals with schizophrenia or bipolar disorder, or any mental illness that causes severe functional impairment. |
Frequently asked questions
COVID-19 Vaccine AstraZeneca is a vaccine used to protect people aged 18 years and older against COVID-19.
COVID-19 is caused by a virus called coronavirus (SARS-CoV-2).
COVID-19 Vaccine AstraZeneca stimulates the body’s natural defences (immune system). It causes the body to produce its own protection (antibodies) against the virus. This will help to protect you against COVID-19 in the future. None of the ingredients in this vaccine can cause COVID-19.
Do not have the vaccine:
If you have ever had a severe allergic reaction to any of the active substances or any of the other ingredients listed in section 6. Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue. Contact your doctor or healthcare professional immediately or go to the nearest hospital emergency room right away if you have an allergic reaction. It can be life-threatening.
If you are not sure, talk to your doctor, pharmacist or nurse.
Warnings and precautions
Tell your doctor, pharmacist or nurse before vaccination:
- If you have ever had a severe allergic reaction (anaphylaxis) after any other vaccine injection;
- If you currently have a severe infection with a high temperature (over 38°C).
However, a mild fever or infection, like a cold, are not reasons to delay vaccination; - If you have a problem with bleeding or bruising, or if you are taking a blood thinning medicine (anticoagulant);
- If your immune system does not work properly (immunodeficiency) or you are taking medicines that weaken the immune system (such as high-dose corticosteroids, immunosuppressants or cancer medicines).
If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before you are given the vaccine.
As with any vaccine, COVID-19 Vaccine AstraZeneca may not protect everyone who is vaccinated from COVID-19. It is not yet known how long people who receive the vaccine will be protected for. No data are currently available in individuals with a weakened immune system or who are taking chronic treatment that suppresses or prevents immune responses.
Children and adolescents
No data are currently available on the use of COVID-19 Vaccine AstraZeneca in children and adolescents younger than 18 years of age.
Other medicines and COVID-19 Vaccine AstraZeneca
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take, any other medicines or vaccines.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, tell your doctor, pharmacist or nurse. There are limited data on the use of COVID-19 Vaccine AstraZeneca in pregnant or breastfeeding women. Your doctor, pharmacist or nurse will discuss with you whether you can be given the vaccine.
Driving and using machines
COVID-19 Vaccine AstraZeneca has no known effect on the ability to drive and use machines. However, side effects listed in section 4 may impact your ability to drive and use machines. If you feel unwell, do not drive or use machines.
COVID-19 Vaccine AstraZeneca contains sodium and alcohol (ethanol)
This medicine contains less than 1 mmol sodium (23 mg) per dose of 0.5 ml. This means that it is essentially ‘sodium-free’.
This medicine contains a very small amount of alcohol (0.002 mg of alcohol (ethanol) per dose of 0.5 ml). This is not enough to cause any noticeable effects.
COVID-19 Vaccine AstraZeneca is injected into a muscle (usually in the upper arm).
You will receive 2 injections. You will be told when you need to return for your second injection of COVID-19 Vaccine AstraZeneca.
The second injection can be given between 4 and 12 weeks after the first injection.
When COVID-19 Vaccine AstraZeneca is given for the first injection, COVID-19 Vaccine AstraZeneca (and not another vaccine against COVID-19) should be given for the second injection to complete vaccination course.
If you miss your second injection
If you forget to go back at the scheduled time, ask your doctor, pharmacist or nurse for advice. It is important that you return for your second injection of COVID-19 Vaccine AstraZeneca.
Like all medicines, this vaccine can cause side effects, although not everybody gets them. In clinical studies with the vaccine, most side effects were mild to moderate in nature and resolved within a few days with some still present a week after vaccination.
If side effects such as pain and/or fever are troublesome, medicines containing paracetamol can be taken.
Side effects that occurred during clinical trials with COVID-19 Vaccine AstraZeneca were as follows:
Very Common (may affect more than 1 in 10 people)
- Like all medicines, this vaccine can cause side effects, although not everybody gets them. In clinical studies with the vaccine, most side effects were mild to moderate in nature and resolved within a few days with some still present a week after vaccination.
- If side effects such as pain and/or fever are troublesome, medicines containing paracetamol can be taken.
- Side effects that occurred during clinical trials with COVID-19 Vaccine AstraZeneca were as follows:
- Very Common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
- a lump at the injection site
- fever
- being sick (vomiting)
- flu-like symptoms, such as high temperature, sore throat, runny nose, cough and chills
Uncommon (may affect up to 1 in 100 people)
- Feeling dizzy
- decreased appetite
- abdominal pain
- enlarged lymph nodes
- excessive sweating, itchy skin or rash
n clinical trials there were very rare reports of events associated with inflammation of the nervous system, which may cause numbness, pins and needles, and/or loss of feeling. However, it is not confirmed whether these events were due to the vaccine.
If you notice any side effects not mentioned in this leaflet, please inform your doctor, pharmacist or nurse.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.
If you are concerned about a side-effect it can be reported directly via the Coronavirus Yellow Card reporting site https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store and include the vaccine brand and batch/Lot number if available. By reporting side effects you can help provide more information on the safety of this vaccine.
One dose (0.5 ml) contains:
COVID-19 Vaccine (ChAdOx1-S* recombinant)
Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike
glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.
This product contains genetically modified organisms (GMOs).
The other excipients are L-histidine, L-histidine hydrochloride monohydrate, magnesium chloride hexahydrate, polysorbate 80, ethanol, sucrose, sodium chloride, disodium edetate dihydrate, water for injections.
What COVID-19 Vaccine AstraZeneca looks like and contents of the pack
Solution for injection. The solution is colourless to slightly brown, clear to slightly opaque and particle free.
